Recurrent Episodes of Hypokalaemia during Treatment with Inhaled Beta-2 Agonist Revealing Gitelman Syndrome, an Uncommon Clinical Entity
  • Nery Sablón-González
    Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
  • Yanet Parodis-Lopez
    Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
  • Maria Belen Alonso-Ortiz
    Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
  • Angélica Laurin
    Centro de Atención Primaria Barrio Atlántico, Las Palmas de Gran Canaria, Spain
  • Emmanuel Andres
    Service de Médecine Interne, Diabète et Maladies Métaboliques. Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Noel Lorenzo Villalba
    Service de Médecine Interne, Diabète et Maladies Métaboliques. Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Keywords

Hypokalemia, metabolic alcalosis, Gitelman syndrome

Abstract

A 28-year-old female patient was hospitalized for mild–moderate hypokalaemia which was persistent despite discontinuation of beta-2 agonist bronchodilator treatment. Her past medical history was relevant for two episodes of severe hypokalaemia after active inhaled beta-2 agonist treatment for asthma crisis. Investigations revealed increased potassium in spot urine with a transtubular potassium gradient <4. A 24-hour urine analysis showed hypophosphaturia, hypocalciuria, hypomagnesuria and normal urine prostaglandins in favour of Gitelman syndrome. Oral potassium supplementation was started and genetic studies were recommended.

VIEW THE ENTIRE ARTICLE

References

  • Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008;3:22.
  • Grillone T, Menniti M, Bombardiere F, Vismara MF, Belviso S, Fabiani F, et al. New SLC12A3 disease causative mutation of Gitelman's syndrome.World J Nephrol 2016 Nov 6;5(6):551–555. doi: 10.5527/wjn.v5.i6.551
  • Molina A, Mon C, Oliet A, Ortiz M. Variabilidad clínica del síndrome de Gitelman. Nefrologia 2006;26:504–506.
  • Yeh FC, Chiang WF, Wang CC, Lin SH. Thyrotoxic periodic paralysis triggered by B2-adrenergic bronchodilators. CJEM 2014 May;16(3):247–251.
  • Al Shibli A, Narchi H. Bartter and Gitelman syndromes: spectrum of clinical manifestations caused by different mutations. World J Methodol 2015;5:55–61.

    • Views: 537
    HTML downloads: 558
    PDF downloads: 309

    Published: 2022-10-20
    Issue: 2022: Vol 9 No 10 (view)

    How to cite:
    1.
    Sablón-González N, Parodis-Lopez Y, Alonso-Ortiz MB, Laurin A, Andres E, Lorenzo Villalba N. Recurrent Episodes of Hypokalaemia during Treatment with Inhaled Beta-2 Agonist Revealing Gitelman Syndrome, an Uncommon Clinical Entity. EJCRIM 2022;9 doi:10.12890/2022_003605.

    Most read articles by the same author(s)

    1 2 > >>